

Detach upside remains

Share Price: \$0.255

Anatara can still partner Detach

On 14 June 2019, Anatara announced that it would retain exclusive rights to Detach for livestock and horses, as Zoetis, Anatara's former partner, returned the exclusive worldwide license for Detach that it had taken in May 2018. Although the deal impacted Anatara's share price at the time and may continue to negatively affect it in the short run, we believe that the company has several other options that can compensate for this loss in the medium to long term. Anatara had engaged with over 10 top multinational animal health companies prior to signing an agreement with Zoetis. Thus, even though the termination of the exclusive commercialisation agreement with Zoetis may slow down the pace of Detach's commercialisation, we believe that Anatara can still find a good partner for the product.

There also remains considerable upside from a human health application

In our 14 March 2019 initiation report on Anatara we looked in some detail at Anatara's bromelain-based Gastrointestinal ReProgramming (GaRP) product. GaRP is being developed for human GI health, particularly in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), as a dietary supplement that could be used by itself or in conjunction with prescription medications. Due to the regulatory and commercial advantages associated with natural products and the complexity of management of these diseases, we believe GaRP has significant upside potential. Anatara's current cash is sufficient to fund GaRP in the human GI space through to the point of licensing out. Milestones and royalty payments will provide funding for future developments. We believe that even if investors are skeptical about Detach in the wake of the Zoetis hand-back, they can still be sanguine about the prospects of GaRP.

Valuation

In March 2019 we valued Anatara at \$1.34 per share base case and \$3.61 optimistic case using a probability-weighted DCF valuation approach. We have adjusted our valuation to take account of the Detach commercial risk. Our new valuation range is \$1.09/\$3.20. We see the potential to be re-rated by the market as GaRP progresses and as Detach gains regulatory approvals.

ASX: ANR


Sector: Healthcare

17 July 2019

Market Cap. (A\$ m)	12.6
# shares outstanding (m)	49.4
# share fully diluted	52.0
Market Cap Ful. Dil. (A\$ m)	13.3
Free Float	100%
12 months high/low	0.835 / 0.2
1 / 3 / 12-month performance	-23% / -49% / -58%
Website	anataralifesciences.com

Source: Company, Pitt Street Research

Share price (A\$) and avg. daily volume (k, r.h.s.)



Source: FactSet, Pitt Street Research

Valuation metrics	
DCF fair valuation range (A\$)	1.09 / 3.20
WACC	15%
Assumed terminal growth rate	None

Source: Pitt Street Research

Subscribe to our research [HERE](#)

Analyst: Stuart Roberts

Tel: +61 (0) 447 247 909

Stuart.roberts@pittstreetresearch.com

The Anatara/Zoetis partnership may be over, but there is still upside for Anatara

There are key milestones in animal health that the company can still achieve

On 14 June 2019, Anatara announced that it would retain exclusive rights to Detach for livestock and horses, as Zoetis, Anatara's former partner, returned the exclusive worldwide license for Detach that it had taken in May 2018. Although the deal impacted Anatara's share price at the time and may continue to negatively affect it in the short run, we believe that the company has several other options that can compensate for this loss in the medium to long term. Anatara had engaged with over 10 top multinational animal health companies prior to signing an agreement with Zoetis. Thus, even though the termination of the exclusive commercialisation agreement with Zoetis may slow down the pace of Detach's commercialisation, we believe that Anatara can still find a good partner for the product.

Moreover, there are key milestones in animal health that the company can still achieve with significant upside potential. It is banking on Detach's regulatory approval in overseas markets, its global and/or regional licensing, launch of the APVMA-approved product in Australia, and its development for species other than piglets.

Considering the significant benefits associated with Anatara products and their ability to attain significant market penetration along with a relatively relaxed regulatory scenario, we believe that the company could soon ink a deal of a similar size and scale in the near future. In fact, our analysis indicates that many animal health and pharma companies would be keen to leverage the potential of Anatara's products. Based on our assessment, Anatara could consider collaborating with top pharma/animal health companies, such as Elanco and Merck, to commercialise Detach in scour and IBD/IBS (Figure 1). All these players are of a comparable size and scale to Zoetis, have a wide geographical footprint and offer products/disease focus similar to Anatara. Moreover, these companies have actively undertaken M&A during the past few years.

Figure 1: Prospective Companies for Exploring Partnership Opportunities

Potential Animal Health Partners	Potential Human Health Partners
Merck Animal Health	Roche
Boehringer Ingelheim Animal Health	Johnson & Johnson
Elanco	Takeda

Source: Pitt Street Research

Our valuation of Antara

We describe our valuation approach in our March 2019 initiation report. With this update we retain the basic assumptions of that time, however we now assume that

- Anatara can re-license Detach to a prospective veterinary medicine player in FY20 (optimistic case) or FY21 (base case);
- The commercial terms for the new deal will be similar to those that prevailed with Zoetis

This plus the recent change in the cash balance has the effect of lowering our valuation range from \$1.34 per share base case and \$3.61 optimistic case to \$1.09 base case / \$3.20 optimistic case.

Figure 2: Our new valuation of Anatara

	Base	Optim.
Detach Global (A\$m)	46.5	135.5
GaRP (A\$m)	7.8	28.5
Value of tax losses	3.2	3.2
Underlying R&D cost	-9.6	-9.6
Cash now (A\$m)	5.4	5.4
Cash from options and cash to be raised (A\$m)	3.4	3.4
Total value (A\$m)	56.8	166.5
Total diluted shares (million)	52.0	52.0
Value per share	\$1.09	\$3.20
Valuation midpoint	\$2.15	
Share price now (A\$ per share)	\$0.255	
Upside to midpoint	742.4%	

Source: Pitt Street Research

Re-rating Anatara

We see a number of factors helping to re-rate Anatara towards our valuation range:

- Registration of Detach in key markets;
- Positive results from efficacy and proof-of-concept studies of GaRP in IBD/IBS;
- Partnering or collaboration events related to GaRP.
- Potentially, a re-licensing of Detach.

We see the potential for Anatara to re-rate even before a re-licensing of Detach



Risks for Anatara

Risks specific to Anatara. We see four major risks for Anatara as a company and as a listed stock:

- **Clinical risk.** There is the risk that GaRP fails to demonstrate expected benefits in efficacy studies for IBD and IBS given the complexity of these diseases.
- **Partnering risk.** There is the risk that Anatara fails to secure a partner for GaRP another partner for Detach.
- **Funding risk.** There is the risk that Anatara's current cashflow exhausts faster than expected and that it does not get enough funding to survive itself through R&D efforts in human GI health.
- **Timing risk.** Commercialization efforts for Detach may be further delayed, impacting the royalty on product sales. Also, efficacy studies with GaRP may take longer than expected.

Risks related to pre-revenue Life Science companies in general. The stocks of biotechnology and medical device companies without revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character. Since most biotechnology and medical device companies listed on the Australian Securities Exchange fit this description, the term 'speculative' can reasonably be applied to the entire sector. The fact that the intellectual property base of most biotechnology and medical device lies in science not generally regarded as accessible to the layman adds further to the riskiness with which the sector ought to be regarded.

Caveat emptor. Investors are advised to be cognizant of the abovementioned specific and general risks before buying any the stock of any biotechnology and medical device stock mentioned on this report, including Anatara.

General advice warning, Disclaimer & Disclosures

Terms & Conditions

The information contained herein ("Content") has been prepared and issued by Pitt Street Research Pty Ltd ACN 626365615 ("Pitt Street Research"), an Authorised Representative (no: 1265112) of BR Securities Australia Pty Ltd. ABN 92 168 734 530, AFSL 456663. All intellectual property relating to the Content vests with Pitt Street Research unless otherwise noted.

Disclaimer

The Content is provided on an as is basis, without warranty (express or implied). Whilst the Content has been prepared with all reasonable care from sources we believe to be reliable, no responsibility or liability shall be accepted by Pitt Street Research for any errors or omissions or misstatements howsoever caused. Any opinions, forecasts or recommendations reflect our judgement and assumptions at the date of publication and may change without notice. Pitt Street Research will not accept any responsibility for updating any advice, views, opinions or recommendations contained in this document.

No guarantees or warranties regarding accuracy, completeness or fitness for purpose are provided by Pitt Street Research, and under no circumstances will any of Pitt Street Research officers, representatives, associates or agents be liable for any loss or damage, whether direct, incidental or consequential, caused by reliance on or use of the Content.

General Advice Warning

The Content has been prepared for general information purposes only and is not (and cannot be construed or relied upon as) personal advice nor as an offer to buy/sell/subscribe to any of the financial products mentioned herein. No investment objectives, financial circumstances or needs of any individual have been taken into consideration in the preparation of the Content.

Financial products are complex, entail risk of loss, may rise and fall, and are impacted by a range of market and economic factors, and you should always obtain professional advice to ensure trading or investing in such products is suitable for your circumstances, and ensure you obtain, read and understand any applicable offer document.

Disclosures

Pitt Street Research has been commissioned to prepare the Content. From time to time, Pitt Street Research representatives or associates may hold interests, transact or hold directorships in, or perform paid services for, companies mentioned herein. Pitt Street Research and its associates, officers, directors and employees, may, from time to time hold securities in the companies referred to herein and may trade in those securities as principal, and in a manner which may be contrary to recommendations mentioned in this document.

Pitt Street Research receives fees from the company referred to in this document, for research services and other financial services or advice we may provide to that company. The analyst has received assistance from the company in preparing this document. The company has provided the analyst with communication with senior management and information on the company and industry. As part of due diligence, the analyst has independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in the report. Diligent care has been taken by the analyst to maintain an honest and fair objectivity in writing this report and making the recommendation. Where Pitt Street Research has been commissioned to prepare Content and receives fees for its preparation, please note that NO part of the fee, compensation or employee remuneration paid will either directly or indirectly impact the Content provided.